Towards a favorable systemic radio-immunotherapy target

Survival probability of Hodgkin's lymphoma (HL) has improved significantly over the past two decades. Monoclonal antibodies against targeted proteins on Reed-Sternberg cells in HL though a popular choice for immunotherapy have yet to demonstrate complete responses. In a new study, researchers have considered the ripple effects of 90Y-daclizumab, a drug which targets CD25+ tumor cells in Hodgkin's Lymphoma during radio-immunotherapy. The results demonstrated 30.4 percent complete and 19.6 percent